In one embodiment, a continuous analyte sensor having more than one working electrode, and configured to reduce or eliminate crosstalk between the working electrodes. In another embodiment, a continuous analyte sensor having more than one working electrode, and configured so that a membrane system has equal thicknesses over each of the electrodes, despite having differing numbers of layers over each of the electrodes. In another embodiment, a configuration for connecting a continuous analyte sensor to sensor electronics. In another embodiment, methods for forming precise windows in an insulator material on a multi-electrode assembly. In another embodiment, a contact assembly for a continuous analyte sensor having more than one working electrode.
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
2.
Multi-State Engagement With Continuous Glucose Monitoring Systems
Multi-state engagement with continuous glucose monitoring (CGM) systems is described. Given the number of people that wear CGM systems and because CGM systems produce measurements continuously, a platform that provides a CGM system may have an enormous amount of data. This amount of data is practically, if not actually, impossible for humans to process. In implementations, a CGM platform includes a data analytics platform that obtains packages of glucose measurements provided by a CGM system and also obtains additional data associated with a user. The data analytics platform generates state information for the user by processing these CGM packages and the additional data, at least in part, by using one or more models. Based on this state information, the data analytics platform controls communication with the user, which may include generating intervention strategies to prevent users from transitioning to a negative state such as discontinuing use of the CGM system.
G06Q 30/0201 - Market modellingMarket analysisCollecting market data
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
3.
SYSTEM AND METHOD FOR TITRATING BASAL INSULIN DOSES
A continuous glucose monitor (CGM)-driven basal insulin titration system and method for patients with Type 2 Diabetes can be adapted to the needs and concerns of subjects just starting on basal insulin therapy. The method uses as inputs historical CGM data, basal insulin dose information, reports of hypoglycemia, and past recommendations and generates an adjusted insulin dose along with a report advising whether to continue the titration process, or to stop. The method can generate a new recommendation on a regular basis (e.g., each day) until it determines an adequate, consistent dose size.
Glucose level measurements of a user are obtained over time, such as from a wearable glucose monitoring device being worn by the user. These glucose level measurements can be produced substantially continuously, such that the device may be configured to produce the glucose level measurements at regular or irregular intervals of time, responsive to establishing a communicative coupling with a different device, and so forth. These glucose level measurements are analyzed to detect deviations from past glucose measurements, such as glucose measurements received earlier in the day or glucose measurements received at corresponding times of one or more preceding days. Indications of detected deviations are provided to the user or communicated elsewhere, such as to a healthcare professional.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
5.
SYSTEMS AND METHODS FOR USING CONTINUOUS KETONE MONITORING TO PROVIDE FITNESS OPTIMIZATION AND DISEASE DIAGNOSIS
Certain aspects of the present disclosure provide a therapy management system configured to monitor analyte levels of a host during a time period using one or more analyte sensors to obtain analyte data, the analyte levels comprising at least glucose levels and ketone levels, and determine a metabolic fitness of the host based, at least in part, on the analyte data. The therapy management system is further configured to provide therapy management guidance to the host based, at least in part, on the determined metabolic fitness to improve the metabolic fitness of the host. The therapy management guidance includes at least one of a diet or meal recommendation for the host, an exercise recommendation for the host, or a lifestyle recommendation for the host.
G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
A method of delivering a medicament to a subject for the treatment of diabetes includes: receiving glucose data and lactate data for the subject; adjusting medicament therapy to be delivered to the subject based at least in part on the glucose data and the lactate data; and delivering the adjusted medicament therapy to the subject.
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
7.
APPARATUSES, SYSTEMS, AND METHODS FOR LINER REMOVAL FOR MEDICAL DEVICES
The present examples relate generally to apparatuses, systems, and methods for deploying a medical device to skin of a host. The apparatuses, systems, and methods may be directed to removing a liner for a medical device so that the medical device may couple to the skin of the host. The medical device may comprise an on-skin wearable medical device.
The present examples relate generally to apparatuses, systems, and methods for deploying a medical device to skin of a host. The apparatuses, systems, and methods may be directed to applicator systems for deployment of the medical device. The medical device may comprise an on-skin wearable medical device. The on-skin wearable medical device may include a transcutaneous analyte sensor.
Implementations relate generally to devices for measuring an analyte in a host. Implementations may provide bodies for placement of at least a portion of an elongate planar sensor. The bodies may comprise sensor modules for mechanical and/or electrical connection with other structures, which may comprise sensor electronics or testing apparatuses for the elongate planar sensor.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
10.
SYSTEM AND METHOD FOR DECISION SUPPORT USING LIFESTYLE FACTORS
Systems and methods are provided relating to open loop decision-making for management of diabetes. People with diabetes face many problems in controlling their glucose because of the complex interactions between food, insulin, exercise, stress, activity, and other physiological and environmental conditions. Established principles of management of glucose sometimes are not adequate because there is a significant amount of variability in how different conditions impact different individuals and what actions might be effective for them. Accordingly, systems and methods according to present principles minimize the impact of the vagaries of diabetes on individuals, i.e., by looking for patterns and tendencies of an individual and customizing the management to that individual. Consequently, the same reduces the uncertainty that diabetes typically is associated with and improves quality of life.
G06Q 10/109 - Time management, e.g. calendars, reminders, meetings or time accounting
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
11.
SYSTEMS AND METHODS FOR USING A POTASSIUM SENSOR TO PROVIDE THERAPY MANAGEMENT GUIDANCE FOR MEDICATION
Certain aspects of the present disclosure provide systems and methods for continuously monitoring potassium data and other analyte and/or non-analyte data of a patient to provide personalized therapy management guidance.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A device for measurement of a concentration of glycated serum protein is disclosed, the device comprising: an analyte sensing portion configured to generate a signal associated with a concentration of a glycated serum protein, the analyte sensing portion comprising a flavin adenine dinucleotide (FAD)-dependent enzyme or an adenosine triphosphate (ATP)- dependent enzyme; a working electrode (WE); and a counter electrode (CE) and/or a reference electrode (RE). Methods of monitoring kidney disease in a subject using the device are also disclosed.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
13.
SYSTEM FOR CONTINUOUS ANALYTE MONITORING AND MEDICAMENT ADMINISTRATION
Certain aspects of the present disclosure provide a wearable apparatus for disease management, the apparatus including a first unit configured to be attached to an epidermis of a user and a second unit configured to be removably attached to the first unit. The first unit includes a first aperture in which a cannula septum can be attached to the first unit, the cannula septum for receiving a cannula of a medicament cartridge, and a second aperture in which an analyte sensor can be attached to the first unit, the analyte sensor configured to generate analyte data based on measured analyte levels of a user. The second unit includes a medicament pump configured to drive dispensing of a medicament from the medicament cartridge, a receptacle for removably receiving the medicament cartridge, and a transmitter and receiver unit for transmitting and receiving data to and from one or more external devices.
Implementations relate generally to devices for measuring an analyte in a host. Implementations as disclosed herein may be directed to improved mechanical and electrical connections between an electronics module (e.g., a reusable wireless transmitter) and a base. Implementations as disclosed herein may further be directed to a reduced size of an on-skin wearable device including a reusable wireless transmitter and a base.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1495 - Calibrating or testing in vivo probes
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
15.
SYSTEMS, APPARATUSES, AND METHODS FOR CARTRIDGES AND REUSABLE APPLICATORS FOR MEDICAL DEVICES
The present apparatuses, systems, and methods relate to apparatuses, systems, and methods for medical devices. More particularly, apparatuses, systems, and methods are provided for applicator systems for medical devices, including cartridges and reusable applicators for medical devices. The applicator systems may include a transcutaneous analyte sensor for deployment to the skin of a host.
The present examples relate generally to patches for medical devices. The medical devices may comprise a transcutaneous analyte sensor applied to the skin of a host. The apparatuses, systems, and methods disclosed may be directed to ease of application and removal of patches, and mitigating the appearance of a dark ring that may form with a patch.
Systems and methods for continuous measurement of an analyte in a host are provided. The system generally includes a continuous analyte sensor configured to continuously measure a concentration of analyte in a host and a sensor electronics module physically connected to the continuous analyte sensor during sensor use, wherein the sensor electronics module is further configured to directly wirelessly communicate sensor information to one or more display devices. Establishment of communication between devices can involve using a unique identifier associated with the sensor electronics module to authenticate communication. Times tracked at the sensor electronics module and the display module can be at different resolutions, and the different resolutions can be translated to facilitate communication. In addition, the frequency of establishing communication channels between the sensor electronics module and the display devices can vary depending upon whether reference calibration information is being updated.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1495 - Calibrating or testing in vivo probes
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
H04B 7/26 - Radio transmission systems, i.e. using radiation field for communication between two or more posts at least one of which is mobile
H04W 4/70 - Services for machine-to-machine communication [M2M] or machine type communication [MTC]
H04W 4/80 - Services using short range communication, e.g. near-field communication [NFC], radio-frequency identification [RFID] or low energy communication
A method of providing performance reports to persons associated with the monitoring of an analyte level, such as blood glucose concentrations in a host, is provided. The performance reports can indicate a measure of an analyte variability of the host over a first analysis time period compared to a measure of analyte variability of the host over one or more other analysis time periods. The analyte level of the host can be received in each of a plurality of sensor readings from a continuous analyte sensor, such as multiple sensor readings per hour, so that the analyte variability that is used in determining the performance report of the host can be based on not just a few metered readings taken by the host, but a plurality of intermittent readings that are taken by a continuous analyte sensor, for example. Various types of performance reports can be generated, such as reports that comprise charts, graphs, tables, and/or other visual indicia of a host's performance during one analysis period versus another analysis period.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
An analyte monitoring sensor configured for in vivo measurement of at least one analyte is provided, the sensor comprising at least one aptamer electrically associated with at least one working electrode, the at least one aptamer configured to undergo a reversible confirmation change in the presence of at least one analyte; a redox moiety coupled to the at least one aptamer; and at least one reference electrode, the at least one reference electrode comprising a reference electrode coating configured to reduce or eliminate leaching of at least one ion therefrom. Methods of extending in vivo performance of the analyte monitoring sensor are also described.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1468 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
21.
MULTI-POLYMER CONTROLLED DRUG RELEASING DEVICES AND METHODS
The present disclosure relates generally to bioactive releasing membranes utilized with implantable devices, such as devices for the detection of analyte concentrations in a biological sample. More particularly, the disclosure relates to novel bioactive releasing membranes, to devices and implantable devices including these membranes, methods for forming the bioactive releasing membranes on or around the implantable devices, and to methods for monitoring analyte levels in a biological fluid sample using an implantable analyte detection device.
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
The present disclosure relates generally to bioactive releasing membranes utilized with implantable devices, such as devices for the detection of analyte concentrations in a biological sample. More particularly, the disclosure relates to drug releasing implantable devices and to methods for improved initial monitoring of analyte levels in a biological fluid sample using an implantable analyte detection device.
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1459 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters invasive, e.g. introduced into the body by a catheter
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61L 15/24 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bondsDerivatives thereof
A61L 15/46 - Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
Certain aspects of the present disclosure provide systems and techniques for seamless and secure health data sharing. An example technique includes receiving a request from a user account of a third-party health system (TPHS) to access a first-party health system (FPHS). The request includes a token indicating that the user account is authenticated with the TPHS. A second token is obtained from the TPHS and indicates a user account type. Upon determining that the user account type is a caregiver account type authenticated with the FPHS, (z) a first screen including at least one dependent account is displayed on a display device, (zz) a second screen including a consent agreement for sharing health data of a selected dependent account from the first screen is displayed on the display device, and (z'z'z) a communication link is established between the FPHS and the TPHS for sharing the health data.
G06F 21/62 - Protecting access to data via a platform, e.g. using keys or access control rules
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
In some embodiments, a method of dynamically adapting treatments to patient risk preferences includes receiving analyte risk preferences of a patient and personalizing an analyte-value utility model for the patient based on the analyte risk preferences, where the personalized analyte-value utility model describes variation in analyte-value utility across a range of analyte values. The method also includes receiving, for each prospective treatment of one or more prospective treatments, one or more predicted analyte values of the patient for the prospective treatment and determining a prediction uncertainty associated with the one or more predicted analyte values.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
A device includes a first conductive layer comprising a working electrode, wherein the working electrode is configured to generate a signal indicative of the concentration. The device further includes a second conductive layer comprising a reference electrode and/or a counter electrode, a distal tip comprising an exposed portion of the first conductive layer and the second conductive layer and characterized by anon-planer surface comprising at least one projection extending from a plane perpendicular to the longitudinal axis, and an electrically insulating material covering the at least a portion of distal tip, wherein the analyte sensor has a mean absolute relative difference over a sensor session of greater than one day that is less than a corresponding analyte sensor differing only in that a distal tip of the corresponding analyte sensor is free of electrically insulating material.
Examples are directed to analyte sensor systems and methods of use thereof. An analyte sensor system may include an electrochemical aptamer-based biosensor configured for use in sensing a target analyte. The biosensor may include a substrate, a reversible redox probe, and an aptamer. The system may include sensor electronics configured to perform operations. The operations may include interrogating the biosensor to determine a current response, determining an adjusted current value to correct for at least one of pH or temperature, and determining an estimated analyte value for the target analyte based on the adjusted current value.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
Described is a system for correcting for artifacts in raw analyte signals by operating, by an analyte sensor, in a first mode and in a second mode, the analyte sensor generating a first raw sensor signal indicative of a first analyte concentration of a host when operated in the first mode and a second raw sensor signal indicative of a second analyte when operated in the second mode; transitioning the analyte sensor from operating in the second mode to operating in the first mode; accessing a first value based at least on the first raw sensor signal taken during a first time period after the transitioning; generating a corrected first value of the raw sensor signal using corrective signal model configured to correct artifacts in the first raw sensor signal resulting from the transitioning; and generating an estimated first analyte concentration based at least on the corrected first value.
Devices and methods for measurement of a hydroxysteroid analyte concentration in a host is provided, including a sensor housing, the sensor housing comprising an implantable analyte sensing portion configured to generate a signal associated with a concentration of a hydroxysteroid analyte, the analyte sensing portion comprising at least one (NAD(P)+)- dependent hydroxysteroid dehydrogenase enzyme; and at least one NAD(P)H oxidase. Detecting a signal corresponding to the hydroxysteroid analyte of the implantable portion after implantation of the implantable portion is also provided.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase
C12Q 1/32 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase involving dehydrogenase
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones
29.
IDENTITY TOKENS FOR SECURE CONNECTION ESTABLISHMENT IN A HEALTH MANAGEMENT SYSTEM
Aspects of the present disclosure provide techniques for using identity tokens to establish a secure wireless connection between a requesting node, such as a health monitoring application, and a target node, such as an analyte sensor system in a health management system. An example method performed by the requesting node includes transmitting an identity token request message that requests an identity token for a target node in the health management system, wherein the identity token request message includes, at least, a certificate of the target node, receiving the identity token for the target node based on the identity token request message, wherein the identity token includes, at least, a certificate status associated with the certificate of the target node, and establishing a connection with the target node when the certificate status, included in the identity token, indicates that the certificate of the target node is valid.
In an embodiment, a system for mitigating diabetic ketoacidosis (DKA) risk for a patient in real-time includes a continuous glucose monitoring (CGM) system configured to generate one or more glucose measurements associated with a cunent glucose level of a patient over a period, one or more memories including executable instructions, and one or more processors in data communication with the one or more memories. The one or more processors are configured to execute the executable instructions to receive glucose measurements for the patient from the CGM system, receive insulin data for the patient, evaluate criteria associated with DKA using first information related to the glucose measurements and second information related to the insulin data, detect a risk of DKA for the patient responsive to a combination of the first information and the second information satisfying the criteria associated with DKA, and alert the patient based on the detected risk.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
31.
SYSTEMS AND METHODS FOR PROVIDING THERAPY MANAGEMENT GUIDANCE RELATED TO DIABETES FOR HEALTH IMPROVEMENT
Certain aspects of the present disclosure provide a therapy management system configured to monitor at least glucose concentration levels of a patient during a first time period using one or more glucose sensors to obtain glucose data, and determine a diabetic state classification of the patient based on the glucose data. The diabetic state classification indicates a diabetic state of the patient and comprises one of: a healthy classification, a pre-diabetic classification, a mild type 2 diabetes (T2D) classification, a severe T2D classification, or a gestational diabetes classification. The therapy management system is further configured to provide personalized feedback to the patient based on the determined diabetic state classification, wherein the personalized feedback comprises a recommendation for at least one of an exercise session, a dietary change, a lifestyle modification, a medication adjustment, or a continuous glucose monitoring wear schedule.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 40/60 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
32.
ANALYTE SENSOR SYSTEM FOR DETECTING MEDICATION ADMINISTRATION
Aspects of the present disclosure provide techniques for detecting medication administration by one or more health management devices in a health management system. An example method performed by an analyte sensor system in the health management system includes receiving an injection of a medication via an injection port of the analyte sensor system, delivering the medication to subcutaneous tissue of a user of the analyte sensor system via a cannula coupled with the injection port, generating, using an analyte sensor of the analyte sensor system, a signal associated with an analyte concentration level of the subcutaneous tissue of the user, processing the signal to generate processed analyte sensor data, wherein the processed analyte sensor data indicates at least the analyte concentration level of the user, and transmitting the processed analyte sensor data to a display device.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
Various examples are directed to systems and methods for using analyte sensor systems such as, for example, analyte sensor and analyte sensor configured to sense a first analyte when operated in a first mode and two cents a second analyte when operated in a second mode. In some examples, a concentration of the first analyte is determined based on a temperature value generated by a temperature sensor. In some examples, an error of an analyte sensor is determined. In some examples, a baseline sensor characteristic is determined.
In some embodiments, a method of automatically adjusting insulin therapy for a patient includes receiving, at a device associated with the patient, one or more glucose measurements generated by a continuous glucose monitoring (CGM) system of the patient for a period. The method also includes determining, at the device, basal insulin data and bolus insulin data of the patient for the period. The method also includes determining, at the device, a relationship between the basal insulin data and the bolus insulin data. The method also includes generating, at the device, an insulin therapy instruction for the patient based on the one or more glucose measurements and the determined relationship between the basal insulin data and the bolus insulin data, where the insulin therapy instruction includes a total bolus amount.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
The present disclosure relates generally to apparatuses and methods of selectively coating along a length of an elongated body with a coating. In some examples, the elongated body is an insertable analyte sensor portion and the coating comprises one or more anti-inflammatory compounds or tissue response modifiers. One or more additional layers are also disclosed that modulate a release rate or an amount of the one or more anti-inflammatory compounds or tissue response modifiers after implantation in interstitial fluid.
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
Data describing glucose measurements is received from a continuous glucose monitoring (CGM) system worn by a user and predicted glucose values during a future time period are generated for the user based on the data. A determination is made that at least one of the predicted glucose values satisfies a threshold value for an alert, which is associated with a prediction horizon that defines an amount of time prior to satisfaction of the threshold value for communicating the alert to the user. Output of the alert is caused responsive to determining that the at least one predicted glucose value satisfies the threshold value for the alert within the prediction horizon, relative to a current time. The prediction horizon is modified based on a user response to the alert. Output of a subsequent instance of the alert is caused based on the modified prediction horizon.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
Methods and apparatus, including computer program products, are provided for remote monitoring. In some example implementations, there is provided a method. The method may include receiving, at a remote monitor, a notification message representative of an event detected, by a server, from analyte sensor data obtained from a receiver monitoring an analyte state of a host; presenting, at the remote monitor, the notification message to activate the remote monitor, wherein the remote monitor is configured by the server to receive the notification message to augment the receiver monitoring of the analyte state of the host; accessing, by the remote monitor, the server, in response to the presenting of the notification message; and receiving, in response to the accessing, information including at least the analyte sensor data. Related systems, methods, and articles of manufacture are also disclosed.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
H04L 67/12 - Protocols specially adapted for proprietary or special-purpose networking environments, e.g. medical networks, sensor networks, networks in vehicles or remote metering networks
H04Q 9/00 - Arrangements in telecontrol or telemetry systems for selectively calling a substation from a main station, in which substation desired apparatus is selected for applying a control signal thereto or for obtaining measured values therefrom
38.
PROVIDING BACKUP COMMUNICATIONS IN AN ANALYTE MONITORING SYSTEM
The present disclosure describes an analyte monitoring system that establishes backup or alternative communication channels that may be used when certain components or connections in the analyte monitoring system become unavailable. The analyte monitoring system may form direct connections between components of the analyte monitoring system and/or select replacement devices when certain components or connections become unavailable.
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
39.
SYSTEMS AND METHODS FOR POWER MANAGEMENT IN ANALYTE SENSOR SYSTEM
An analyte sensor system may include a first communication circuit configured to transmit a wireless signal in a first communication mode and a second communication mode, and a processor, wherein the processor determines whether a first condition is satisfied, the first condition relating to the sensor signal or to communication by the first communication circuit, and shifts the system to a second communication mode responsive to the first condition being satisfied.
Systems, devices, and methods are disclosed for wireless communication of analyte data. In this regard, embodiments are directed to systems, devices, and methods for identifying a device or analyte sensor system for connection. For example, systems, devices, and methods involve a display device receiving input that identifies an analyte sensor system from among a set of analyte sensor systems and the display device selecting the analyte sensor system for connection, based on the input. In some embodiments, the input is identification information associated with the analyte sensor system and comprises a number string associated with the analyte sensor system which uniquely identifies the analyte sensor system.
41.
APPLICATORS FOR APPLYING TRANSCUTANEOUS ANALYTE SENSORS AND ASSOCIATED METHODS OF MANUFACTURE
Applicators for applying an on-skin assembly to skin of a host and methods of their use and/or manufacture are provided. An applicator includes an insertion assembly configured to insert at least a portion of the on-skin assembly into the skin of the host, a housing configured to house the insertion assembly, the housing comprising an aperture through which the on-skin assembly can pass, an actuation member configured to, upon activation, cause the insertion assembly to insert at least the portion of the on-skin assembly into the skin of the host, and a sealing element configured to provide a sterile barrier and a vapor barrier between an internal environment of the housing and an external environment of the housing.
42.
SYSTEMS AND METHODS FOR REMOTE AND HOST MONITORING COMMUNICATIONS
Systems and methods for remote and host monitoring communication are disclosed. In some implementations, monitoring systems can comprise a host monitoring device associated with a Host communicatively coupled to one or more remote monitoring devices associated with Remote Monitors. The host monitoring device can send communications based at least in part on analyte measurements of a Host sensor and/or other contextual data giving such measurements context. Different remote monitoring devices can receive different communications based at least in part on the role of the respective Remote Monitors relative to the Host. These roles can be reflected in classifications of Remote Monitors.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/155 - Devices for taking samples of blood specially adapted for continuous or multiple sampling, e.g. at predetermined intervals
A61B 5/157 - Devices for taking samples of blood characterised by integrated means for measuring characteristics of blood
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
Certain aspects of the present disclosure relate generally to configuring applications used in conjunction with medical devices in order to help with monitoring and improving the patient's health. Certain aspects include a method including receiving a request for assets including access information associated with a user of a computing device, the access information including feature customization information for a health intervention application and being issued by an account management service for the health intervention application, and validating that the access information is valid. The method may also include responsive to the validating, generating configuration information identifying a set of assets with which the health intervention application is to be provisioned based, at least in part, on the feature customization information included in the access information, and transmitting the configuration information to the health intervention application to configure the health intervention application with the identified set of assets.
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
44.
OPTICAL-BASED POWER ACTIVATION TECHNIQUES FOR AN ANALYTE SENSOR SYSTEM
Aspects of the present disclosure provide techniques for optical-based power activation for an analyte sensor system. The analyte sensor system includes an analyte sensor configured to generate analyte measurements associated with a user and a light¬ sensitive component is configured to generate an output signal based on the light energy. The light-sensitive component is disposed underneath an aperture and on a top side of a circuit board facing a top side of a housing of the analyte sensor system. The analyte sensor system further includes a sensor electronics module configured to receive, in a low-power mode, the output signal from the light-sensitive component, switch the sensor electronics module from the low-power mode to a high-power mode based on the output signal, receive, in the high-power mode, the analyte measurements from the analyte sensor, and transmit analyte data associated with the analyte measurements to a display device.
A device for generating alerts for Hypo and Hyperglycemia Prevention from Continuous Glucose Monitoring (CGM) determines a dynamic risk based on both information of glucose level and a trend obtainable from a CGM signals. The device includes a display whose color depends on the DR (for example, red for high DR, green for low risk). When DR exceeds a certain threshold, alerts are generated to suggest the patient to pay attention to the current glucose reading and to its trend, both of which are shown on the display in numbers and symbols (e.g. an arrow with different slope or color).
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
Aspects of the present disclosure provide an analyte sensor system for communication with a partner device in a health management system. The analyte sensor system includes a transcutaneous analyte sensor configured to perform one or more analyte concentration level measurements of a user of the analyte sensor system and an antenna system for communicating with the partner device. The antenna system includes a plurality of antennas and each antenna of the plurality of antennas has a different polarization. The analyte sensor system is configured to transmit an analyte data, associated with the one or more analyte concentration level measurements of the user, to a partner device using one or more antennas of the plurality of antennas. Additionally, the analyte sensor system is configured to receive one or more signals from the partner device using one or more antennas of the plurality of antennas.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
The present invention relates generally to systems and methods for processing, transmitting, and displaying data received from continuous analyte sensor, such as a glucose sensor. In some embodiments, the continuous analyte sensor system comprises a sensor electronics module that includes power saving features. One feature includes a low power measurement circuit that can be switched between a measurement mode and a low power mode, in which charging circuitry continues to apply power to electrodes of a sensor during the low power mode. In addition, the sensor electronics module can be switched between in a low power storage mode higher power operational mode via a switch. The switch can include a reed switch or optical switch, for example. A validation routine can also be implemented to ensure an interrupt signal sent from the switch is valid. The continuous analyte sensor can be physically connected to a sensor electronics module, which is in direct wireless communication with a plurality of different display devices.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/1468 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
G06F 1/3203 - Power management, i.e. event-based initiation of a power-saving mode
G06F 1/3287 - Power saving characterised by the action undertaken by switching off individual functional units in the computer system
G08C 17/02 - Arrangements for transmitting signals characterised by the use of a wireless electrical link using a radio link
50.
SYSTEMS AND METHODS FOR COMPUTING GLYCEMIC CONTROL CHANGE
The present disclosure describes an analyte monitoring system that tracks a host's glycemic control levels over time to determine disease progression. The analyte monitoring system may then administer a treatment to address the disease progression.
In certain embodiments, a method for providing notifications on a display device is provided. Measured analyte data are received, at a current time, from a continuous analyte monitoring (CAM) system worn by a user. In response to receiving the measured analyte data, a time-in-range (TIR) tally count is determined based on the current time and the measured analyte data, and a TIR tally goal is determined based on the current time and a TIR daily goal. A TIR tally notification is generated, and then presented to the user in a graphical user interface (GUI). The TIR tally notification includes the TIR tally count, the TIR tally goal, and a TIR tally goal progress bar. The measured analyte data are periodically received based on a measurement time period, and the TIR tally notification is periodically generated based on a TIR tally time period.
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
A system for authenticating a user comprises one or more memories comprising executable instructions and data and one or more processors configured to execute the executable instructions. The instructions, when executed, cause the one or more processors to send a login request for a user to a server over a network, the login request comprising a username and a password; in response to a successful login, send a request for location information associated with the user to the server over the network, the location information comprising a trusted user flag and a country of residence (COR); and in response to the trusted user flag indicating that the user is trusted, execute one or more features of an application.
Systems and methods are described for determining a reference blood glucose (RefBG) metric and for determining a medicament dose or dose adjustment for a subject based at least in part the reference blood glucose metric. The RefBG metric is based on continuous and/or intermittent glucose monitoring samples and can be derived from a specified time window of the samples. One or more additional metrics of a therapeutic performance of the subject may be modeled and used to establish a target value for the RefBG metric, which may be compared to historical RefBG values to determine dose values to be avoided in future updates of medicament doses.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
54.
PROXIMITY PAIRING AND SECURITY OF A CONTINUOUS ANALYTE SENSOR SYSTEM
Techniques and protocols for facilitating wireless secure communications between a sensor system and one or more other devices are disclosed. In certain embodiments, the techniques and protocols include secure proximity pairing techniques with reduced power. A method for pairing an analyte sensor system and one or more display devices includes broadcasting, from the analyte sensor system, for an initial connection, a low power general advertisement including an indication indicating the low power general advertisement is for proximity pairing. The method includes receiving, from a first display device, a connection request message in response to the low power general advertisement; performing an authentication procedure with the first display device; and pairing and bonding with the first display device based on successful authentication with the first display device.
Systems and methods are provided to provide guidance to a user regarding management of a physiologic condition such as diabetes. The determination may be based upon a patient glucose concentration level. The glucose concentration level may be provided to a stored model to determine a state. The guidance may be determined based at least in part on the determined state.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 70/20 - ICT specially adapted for the handling or processing of medical references relating to practices or guidelines
56.
BAYESIAN FRAMEWORK FOR PERSONALIZED MODEL IDENTIFICATION AND PREDICTION OF FUTURE BLOOD GLUCOSE IN TYPE 1 DIABETES USING EASILY ACCESSIBLE PATIENT DATA
A method of predicting future blood glucose concentrations of an individual patient includes: selecting an individualized nonlinear physiological model of glucose-insulin dynamics, the selected model having a plurality of model parameters whose values are to be determined; estimating values for each of the model parameters in the plurality of model parameters, a first subset of the model parameters having values estimated from a priori population data and a second subset of the model parameters having values personalized for the individual patient by applying a parameter estimation technique to a priori information and data for the individual patient to obtain a posteriori information; and; applying a nonlinear prediction technique to the selected model using the estimated values for each of the model parameters to obtain a predicted blood glucose concentration of the individual patient at a future time.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
57.
COMPATIBILITY CHECK FOR CONTINUOUS GLUCOSE MONITORING APPLICATION
Disclosed are systems, methods, and articles for determining compatibility of a mobile application and operating system on a mobile device. In some aspects, a method includes receiving one or more data values from a mobile device having a mobile medical software application installed thereon, the data value(s) characterizing a version of the software application, a version of an operating system installed on the mobile device, and one or more attributes of the mobile device; determining whether the mobile medical software application is compatible with the operating system by at least comparing the received data value(s) to one or more test values in a configuration file; and sending a message to the mobile device based on the determining, the message causing the software application to operate in one or more of a normal mode, a safe mode, and a non-operational mode.
G06F 11/14 - Error detection or correction of the data by redundancy in operation, e.g. by using different operation sequences leading to the same result
G06F 11/36 - Prevention of errors by analysis, debugging or testing of software
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
H04L 67/00 - Network arrangements or protocols for supporting network services or applications
H04M 1/724 - User interfaces specially adapted for cordless or mobile telephones
H04M 1/72403 - User interfaces specially adapted for cordless or mobile telephones with means for local support of applications that increase the functionality
Methods and apparatus, including computer program products, are provided for processing analyte data. In some example implementations, a method may include generating glucose sensor data indicative of a host's glucose concentration using a glucose sensor; calculating a glycemic variability index (GVI) value based on the glucose sensor data; and providing output to a user responsive to the calculated glycemic variability index value. The GVI may be a ratio of a length of a line representative of the sensor data and an ideal length of the line. Related systems, methods, and articles of manufacture are also disclosed.
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G01N 33/49 - Physical analysis of biological material of liquid biological material blood
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
59.
GENERATIVE ARTIFICIAL INTELLIGENCE VALIDATION PROCESS
In some aspects, a method of automated machine learning model validation. The method includes generating content using a machine leaning model. The method includes providing, to a grader machine learning model, the content along with a prompt instructing the grader machine learning model to evaluate the content according to one or more metrics, wherein the prompt includes, for each metric of the one or more metrics: a natural language definition of the metric; and one or more examples of content items that pass or fail the metric. The method includes receiving, from the grader machine learning model in response to the prompt, an evaluation of the content according to the one or more metrics. The method includes performing one or more actions related to the machine learning model based on the evaluation.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Examples of invasive biosensor alignment and retention features and methods are described. One example biosensor includes a housing comprising: a first surface defining a first opening, and a second surface opposite the first surface, the second surface defining a second opening, the first and second openings defining a substantially unobstructed pathway through the housing; a biosensor wire partially disposed within the housing and having an exterior portion extending through the first opening; a hollow insertion needle positioned within the pathway and extending through the first opening, the hollow insertion needle at least partially encircling the biosensor wire; and a biosensor retention feature collapsible against the first surface of the housing, the biosensor retention feature encircling and contacting the hollow insertion needle.
Systems, devices, and methods are disclosed for wireless communication of analyte data. In this regard, in embodiments, a mobile includes a transceiver configured to transmit and receive wireless signals. The mobile device includes circuitry operatively coupled to the transceiver. The mobile device also includes a non-transitory computer-readable medium operatively coupled to the circuitry and storing instructions that, when executed, cause the mobile device to perform a number of operations. One such operation is to obtain a derivative of a first signal received via a first link. Another such operation is to obtain a derivative of a second signal received via a second link; and. Yet another such operation is to generate a selection for connection to an analyte sensor system, based on a comparison of the derivative of the first signal and the derivative of the second signal.
H04Q 9/00 - Arrangements in telecontrol or telemetry systems for selectively calling a substation from a main station, in which substation desired apparatus is selected for applying a control signal thereto or for obtaining measured values therefrom
User interfaces for glucose insight presentation are leveraged. A glucose monitoring application is configured to process glucose measurements to determine one or more glucose insights, e.g., about a user's glucose. The glucose measurements, for example, may be obtained from a glucose monitoring device that collects glucose measurements of the user at predetermined intervals, e.g., every five minutes. The glucose monitoring application configures a user interface, based on configuration data, to present one or more visual elements representative of the one or more glucose insights. For example, the glucose monitoring application may configure the user interface to include a visual element in the form of a color field which represents whether the user's current glucose measurement (e.g., the most recent glucose measurement obtained from the glucose monitoring device) is below, within, or above a glucose range.
Aspects of the present disclosure provide techniques for adapting an advertisement rate at which advertisement messages are transmitted by an analyte sensor system. An example method performed by the analyte sensor system includes transmitting first advertisement messages according to a first advertisement rate, establishing a connection with a display device based on the first advertisement messages, receiving, from the display device after establishing the connection, a message requesting the analyte sensor system use a second advertisement rate, determining the second advertisement rate based on the message, terminating the connection with the display device, transmitting, after the connection with the display device is terminated, second advertisement messages according to the second advertisement rate, and reestablishing the connection with the display device based on the second advertisement messages. Other aspects relate to adapting measurement data transmission rates and authentication/authorisation of display devices and encryption of (re-)established connections.
H04L 67/12 - Protocols specially adapted for proprietary or special-purpose networking environments, e.g. medical networks, sensor networks, networks in vehicles or remote metering networks
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
H04L 69/28 - Timers or timing mechanisms used in protocols
H04W 4/80 - Services using short range communication, e.g. near-field communication [NFC], radio-frequency identification [RFID] or low energy communication
Electric potential signals are applied between a reference electrode and a working electrode of an analyte sensor to determine conditions that may impact the performance of the analyte sensor. At least one of alternating current techniques or direct current techniques may be implemented to detect conditions that impact the performance of the analyte sensor.
Various examples are directed to analyte sensor systems and methods of use thereof. An analyte sensor system may comprise a first analyte sensor comprising a first electrode, a membrane positioned at least partially over the first electrode, and sensor electronics. The sensor electronics may be configured to provide an excitation signal between the first electrode and a second electrode. The analyte sensor system may be configured for the excitation signal to induce a current between the first electrode and the second electrode at least partially outside the membrane.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
A61B 5/1495 - Calibrating or testing in vivo probes
A61B 5/053 - Measuring electrical impedance or conductance of a portion of the body
66.
CONTINUOUS GLUCOSE MONITOR COMMUNICATION WITH MULTIPLE DISPLAY DEVICES
A continuous glucose monitor for wirelessly transmitting data relating to glucose value to a plurality of displays is disclosed, as well as systems and methods for limiting the number of display devices that can connect to a continuous glucose transmitter. In addition, security, including hashing techniques and a changing application key, can be used to provide secure communications between the continuous glucose transmitter and the displays. Also provided is a continuous glucose monitor and techniques for authenticating multiple displays, providing secure data transmissions to multiple displays, and coordinating the interaction of commands and data updates between multiple displays.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
G09G 5/00 - Control arrangements or circuits for visual indicators common to cathode-ray tube indicators and other visual indicators
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16Z 99/00 - Subject matter not provided for in other main groups of this subclass
H04W 76/11 - Allocation or use of connection identifiers
Certain aspects of the present disclosure relate to methods and systems for providing decision support around glucose management for patients with diabetes. Time-varying inputs including blood glucose, meal intake information, and amount of infused insulin are processed using a machine learning model to obtain predicted glucose levels for a plurality of prediction horizons and uncertainties for the predictions. A confidence interval is generated for each prediction and the confidence intervals are compared to hypo- and hyperglycemic thresholds. If a confidence interval is entirely below or entirely above the hypo- and hyperglycemic thresholds, respectively, then a decision support output is provided.
Examples are directed to analyte sensor systems and methods of use thereof. An analyte sensor system may include an analyte sensor configured to generate a raw sensor signal, and sensor electronics configured to generate analyte values from the raw sensor signal and perform operations. The operations may include determining, after insertion and during break-in of the analyte sensor, an impedance parameter of an analyte sensor a plurality of times to provide impedance measurements, determining during the break- in, using the impedance measurements, one or more conditions of the analyte sensor that affect an ability of the analyte sensor to accurately generate analyte values, determining whether the analyte sensor is ready to accurately generate analyte values in a sensing session based on the one or more conditions, and enabling the sensing session when the analyte sensor is determined to be ready to accurately generate analyte values.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
A61B 5/1495 - Calibrating or testing in vivo probes
An unsupervised method of detecting a pressure induced sensor artifact (PISA) in an analyte signal includes receiving an analyte trace having a plurality of data samples obtained over a period of time. A plurality of predetermined features reflective of a PISA in the analyte trace is extracted to produce a plurality of data points in a feature space defined by the plurality of predetermined features. The data points in the feature space are analyzed using an unsupervised anomaly detection algorithm to produce an anomaly score for each of the data points. Data points that have an anomaly score that exceeds a threshold are identified. An alert is generated indicating that a PISA is present in data samples associated with the data points that have an anomaly score that exceeds the threshold.
In accordance with a method of detecting a pressure induced sensor artifact (PISA) in an analyte trace, a measured analyte trace having a plurality of data samples obtained over a period of time from an analyte sensor is received. A reconstructed analyte trace and an associated confidence window is generated from the measured analyte trace using a Bayesian denoising algorithm that includes a model that models the measured analyte trace as a sum of an unknown true analyte trace and a measurement error. The measured analyte trace is compared to the reconstructed analyte trace to identify data samples in the measured analyte trace that are located outside of the confidence window as being associated with a PISA.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
In an embodiment, a method of dynamically adapting analyte rate-of-change determination to a current patient context includes receiving, from a continuous analyte monitoring system, a plurality of analyte measurements of a patient. The method also includes automatically determining a current context for the patient based on the plurality of analyte measurements. The method also includes automatically configuring an analyte rate-of-change determination based on the current context. The method also includes generating a context-adapted rate-of-change measurement based on the automatically configured analyte rate-of-change determination and the plurality of analyte measurements.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
73.
OPTIMIZED TRANSMISSION OF ANALYTE DATA IN MULTI-RECEIVER ENVIRONMENTS
In an embodiment, one general aspect includes a method of optimizing data transmission from a device to a remote target. The method includes receiving analyte measurements from a continuous analyte monitoring (CAM) system. The method also includes determining a current status of a connection between the device and the CAM system. The method also includes conditionally transmitting data related to the analyte measurements over a network to a remote target based on the current status of the connection.
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
74.
OPTIMIZING EVENT IDENTIFICATION BY PERFORMING PATIENT-SPECIFIC ANALYTE DATA TRANSFORMS
In an embodiment, a method of optimizing analyte event identification includes receiving, from a continuous analyte monitoring system, first analyte measurements determined for a patient during a first time period. The method also includes transforming the first analyte measurements into first relevance metrics that each indicate a probability of an occurrence of a defined analyte event during the first time period. The method also includes generating a personalized analyte signature for the patient for the first time period based on the first relevance metrics. The method also includes automatically identifying one or more analyte events for the patient based on an evaluation of additional analyte measurements determined for the patient relative to the personalized analyte signature for the patient.
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
75.
SYSTEMS FOR DETERMINING SIMILARITY OF SEQUENCES OF GLUCOSE VALUES
In implementations of systems for determining a similarity of sequences of glucose values, a computing device implements a similarity system to receive input data describing a sequence of user glucose values measured by a continuous glucose monitoring (CGM) system. The similarity system computes similarity scores for a plurality of sequences of glucose values by comparing each glucose values included in the sequence of user glucose values with ever glucose value included in each sequence of the plurality of sequences. A particular sequence of glucose values that is associated with a highest similarity score is identified. The similarity system determines an externality associated with the particular sequence. The similarity system generates an indication of the externality for display in a user interface.
Various examples are directed to systems and methods for generating an estimated analyte value. An analyte sensor system may access a first sensor signal from an in vivo analyte sensor and a first temperature signal from the ex vivo temperature sensor. The analyte sensor system may generate a first analyte sensor temperature based at least in part on the first temperature signal and generate a first estimated analyte value based at least in part on the first sensor signal and the first temperature-compensated sensitivity.
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
A61B 5/1468 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means
77.
SEAMLESS AND CONTINUOUS AUTHENTICATION OF PATIENTS
Systems, techniques, and devices for performing passive continuous authentication of a user of display device are disclosed. In certain embodiments, the techniques include obtaining first information including at least one of (i) non-analyte sensor data from one or more sensors of a display device or (ii) analyte sensor data from an analyte sensor system. The techniques further include authenticating an identity of the user of the display device at a first point in time and based on the first information. The techniques further include allowing the user of the display device to access a medical device software running on the display device without prompting the user for authentication information, upon determining that the authentication at the first point in time is successful.
G06F 21/32 - User authentication using biometric data, e.g. fingerprints, iris scans or voiceprints
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
78.
DIABETES MANAGEMENT PARTNER INTERFACE FOR WIRELESS COMMUNICATION OF ANALYTE DATA
Systems, devices, and methods are disclosed for wireless communication of analyte data. In embodiments, a method of using a diabetes management partner interface to configure an analyte sensor system for wireless communication with a plurality of partner devices is provided. The method includes the analyte sensor system receiving authorization to provide one of the partner devices with access to a set of configuration parameters via the diabetes management partner interface. The set of configuration parameters is stored in a memory of the analyte sensor system. The method also includes, responsive to input received from the one partner device via the diabetes management partner interface, the analyte sensor system setting or causing a modification to the set of configuration parameters, according to a system requirement of the one partner device.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1495 - Calibrating or testing in vivo probes
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 10/65 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records stored on portable record carriers, e.g. on smartcards, RFID tags or CD
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
H04W 4/38 - Services specially adapted for particular environments, situations or purposes for collecting sensor information
H04W 4/80 - Services using short range communication, e.g. near-field communication [NFC], radio-frequency identification [RFID] or low energy communication
The present embodiments relate generally to applicators of on-skin sensor assemblies for measuring an analyte in a host, as well as their method of use and manufacture. In some aspects, an applicator for applying an on-skin sensor assembly to a skin of a host is provided. The applicator includes an applicator housing, a needle carrier assembly comprising an insertion element configured to insert a sensor of the on-skin sensor assembly into the skin of the host, a holder releasably coupled to the needle carrier assembly and configured to guide the on-skin sensor assembly while coupled to the needle carrier assembly, and a drive assembly configured to drive the insertion element from a proximal starting position to a distal insertion position, and from the distal insertion position to a proximal retraction position.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
Various examples are directed to analyte sensor systems and methods. For example, an analyte sensor system may comprise an analyte sensor to generate a raw sensor signal, a temperature sensor positioned remote from the analyte sensor and configured to generate a raw temperature signal, and sensor electronics. The sensor electronics may generate a desired sensor signal and generate an analyte concentration based at least in part on the desired sensor signal. The generating of the desired sensor signal may be based at least in part on the raw temperature signal.
Various examples are directed to analyte sensor systems and methods of using analyte sensor systems. For example, it may be determined that an analyte sensor of the analyte sensor system was inserted into an interstitial region of a host at an insertion time. After the insertion time, a first value of a raw sensor signal generated by the analyte sensor may be sampled. A first estimated interstitial analyte concentration may be determined based on the first value of the raw sensor signal. An offset value may be added to the first estimated interstitial analyte concentration to generate a first estimated blood analyte concentration for the host.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
A61B 5/1495 - Calibrating or testing in vivo probes
82.
SENSOR SYSTEM WITH IMPROVED GLUCOSE VALUE ESTIMATES
An analyte sensor system may include an analyte sensor configured to generate a raw sensor signal associated with an analyte concentration of a host. Sensor electronics may be configured to generate estimated analyte values from the raw sensor signal, determine a rate of change for the estimated analyte values or the raw signal, determine a working electrode temperature, and determine an elapsed time since sensor insertion. The sensor electronics may improve sensor performance by determining a prediction horizon as a function of at least one of the elapsed time and the working electrode temperature, determining a time-lag- compensated estimated analyte value for one of the estimated analyte values as a function of the determined prediction horizon and the rate-of-change, and adjusting estimated analyte values by applying a correction that is a function of the estimated analyte values.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1495 - Calibrating or testing in vivo probes
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Various examples are directed to a glucose sensor comprising a working electrode to support an oxidation reaction and a reference electrode to support a redox reaction. The reference electrode may comprise silver and silver chloride. The Glucose sensor may also comprise an anti-mineralization agent positioned at the reference electrode to reduce formation of calcium carbonate at the reference electrode.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1468 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means
C09D 133/08 - Homopolymers or copolymers of acrylic acid esters
G01N 27/30 - Electrodes, e.g. test electrodesHalf-cells
Certain aspects of the present disclosure relate to methods and systems for calibrating a continuous analyte sensor system while considering the effects or influence of manufacturing conditions experienced by a sensor. In certain aspects, the system determines a sensitivity value for the analyte sensor system and determines, based on the sensitivity value and a manufacturing parameter representing a condition experienced by the analyte sensor system during manufacturing of the analyte sensor system, a calibration parameter for the analyte sensor system. The system also configures the analyte sensor system to convert an electrical current generated by the analyte sensor system into an analyte concentration using the calibration parameter.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
A61B 5/1495 - Calibrating or testing in vivo probes
85.
TEMPERATURE CHARACTERISTIC TO PREDICT PROGRESSIVE SENSOR DECLINE
Described is a system for detecting the onset of Progressive Sensor Decline (PSD) by receiving a first analyte signal associated with a raw analyte measurement of a host from an analyte sensor within a first time period; receiving a first temperature signal associated with a first temperature measurement of the host from a temperature sensor within the first time period; determining a first relationship between the first analyte signal and the first temperature signal; receiving a second analyte signal associated with a raw analyte measurement of the host from the analyte sensor within a second time period; receiving a second temperature signal associated with a second temperature measurement of the host from the temperature sensor within the second time period; determining a second relationship between the second analyte signal and the second temperature signal; and determining an onset of sensor sensitivity degradation of the analyte sensor based on the first and second relationships.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
Described is a system for an adaptive filter for removing temperature- related artifacts by generating a first raw analyte signal associated with an analyte measurement of a host within a first time period; generating a first temperature signal associated with a first temperature measurement of the host within the first time period: detecting a temperature characteristic in the temperature signal exceeding a predetermined threshold; applying the analyte signal and the temperature signal to an adaptive filter to dynamically update filter coefficients based on the analyte signal and the temperature signal; applying the updated filter coefficients to a signal filter to generate a corrective signal; and generating a corrected analyte signal by applying the corrective signal to the analyte signal.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1495 - Calibrating or testing in vivo probes
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
87.
Display screen or portion thereof with graphical user interface
The present disclosure relates to techniques for receiving glucose data from a continuous glucose sensor and controlling the use and redistribution of that data so it is used in an intended manner. In one aspect, a method includes preparing data including glucose levels using a continuous glucose sensor unit; wirelessly transmitting the data relating to the glucose levels to a display device from the continuous glucose sensor unit; automatically forwarding the data relating to the glucose levels from the display device to a cloud computing architecture; and storing the data relating to the glucose levels in separate groups at the cloud computing architecture.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
89.
CONTINUOUS GLUCOSE MONITOR COMMUNICATION WITH MULTIPLE DISPLAY DEVICES
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
90.
TRANSCUTANEOUS ANALYTE SENSORS, APPLICATORS THEREFOR, AND ASSOCIATED METHODS
The present embodiments relate generally to systems and methods for measuring an analyte in a host. More particularly, the present embodiments provide sensor applicators and methods of use with activation that implant the sensor, withdraw the insertion needle, engage the transmitter with the housing, and disengage the applicator from the housing. Systems and methods according to present principles allow for such steps to occur without significant loss of spring force, and without deleterious effects such as seal slingshotting.
Systems and methods are described for interfacing a computing device and a user to display data pertaining to user intake of a substance or user glucose concentration values. . The described systems and methods are generally described in the field of diabetes management, but are applicable to other medical reports as well. In one implementation, a screen for display has a indicator to indicate how the user intake of a substance tends to increase or decrease analyte concentration values or glucose concentration values.
The present embodiments relate generally to applicators of on-skin sensor assemblies for measuring an analyte in a host, as well as their method of use and manufacture. In some aspects, an applicator for applying an on-skin sensor assembly to a skin of a host is provided. The applicator includes an applicator housing, a needle carrier assembly comprising an insertion element configured to insert a sensor of the on-skin sensor assembly into the skin of the host, a holder releasably coupled to the needle carrier assembly and configured to guide the on-skin sensor assembly while coupled to the needle carrier assembly, and a drive assembly configured to drive the insertion element from a proximal starting position to a distal insertion position, and from the distal insertion position to a proximal retraction position.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
Techniques and protocols for establishing secure communications between a display device, a sensor system, and a server system are disclosed. In certain embodiments, the techniques and protocols include secure diabetes device identification techniques and protocols, user-centric mutual authentication techniques and protocols, and device-centric mutual authentication techniques and protocols.
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
Aspects of the present disclosure provide techniques for measuring an ion concentration level of a user of a wearable device. An example method performed by the wearable device includes applying, using a potentiostat of the wearable device, a bias voltage to an ion selective electrode (ISE) of a transcutaneous ion sensor of the wearable device, measuring a current associated with the ISE of the transcutaneous ion sensor, adjusting the bias voltage based on the measured current associated with the ISE until the measured current is within a threshold range, determining, based at least in part on the measured current, the ion concentration level of the user, and transmitting an indication of the ion concentration level of the user to a display device for display to the user.
The present embodiments relate generally to systems and methods for measuring an analyte in a host. More particularly, the present embodiments provide sensor applicators and methods of use to insert the sensor into an individual's skin. Applicators are disclosed for inserting the sensor. Such applicators may be reusable applicators configured to implant multiple different sensors.
This document discusses, among other things, systems and methods to compensate for the effects of temperature on sensors, such as analyte sensor. An example method may include determining a temperature-compensated glucose concentration level by receiving a temperature signal indicative of a temperature parameter of an external component, receiving a glucose signal indicative of an in vivo glucose concentration level, and determining a compensated glucose concentration level based on the glucose signal, the temperature signal, and a delay parameter.
A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 5/1486 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means using enzyme electrodes, e.g. with immobilised oxidase
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
98.
ARTIFICIAL INTELLIGENCE SYSTEM FOR MANAGING ANALYTE CONCENTRATIONS
The present disclosure relates to an analyte monitoring system that implements various features using artificial intelligence to assist the user in addressing or remediating metabolic events. For example, the system analyze images or text narratives using artificial intelligence to detect user actions and link the user actions to metabolic events. As another example, the system may use artificial intelligence to provide recommendations or responses to users. The system may use artificial intelligence to predict meal duration, and the system may group data to reduce input data to a machine learning model.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Various examples are directed to systems and methods for generating a bolus dose for a host. A bolus application may display a first bolus configuration parameter question at a user interface and receive, through the user interface, a first answer to the first bolus configuration parameter question. The first answer may describe a previous bolus determination technique of the host. The bolus application may select a second bolus configuration parameter question using the first answer and provide the second bolus configuration parameter question at the user interface. The bolus application may determine a set of at least one bolus configuration parameter using the first answer and a second answer to the second bolus configuration parameter question.
A61M 5/172 - Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters electrical or electronic
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
100.
TIME SYNCHRONIZATION TECHNIQUES FOR ANALYTE SENSOR SYSTEM
Aspects of the present disclosure provide an analyte sensor system, including a transcutaneous analyte sensor an analog front end (AFE), and a micro controller unit (MCU). The AFE may be configured to perform, using the transcutaneous analyte sensor, one or more measurements associated with a user during at least a first measurement interval and perform one or more actions to maintain time synchronization associated with the MCU retrieving the one or more measurements from the AFE. The MCU may be configured to operate in a sleep mode during the at least the first measurement interval, exit the sleep mode and retrieve the one or more measurements for the first measurement interval from the AFE based on the one or more actions, and transmit data associated with the one or more measurements to a display device for display to the user.
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
